Does primary androgen-deprivation therapy improve survival for localized prostate cancer?

Stacy Loeb, Edward M. Schaeffer

Research output: Contribution to journalArticlepeer-review


Despite a lack of data, many patients receive primary androgen-deprivation therapy (PADT) for the treatment of localized prostate cancer. To evaluate the association between PADT and survival, a population-based cohort study was conducted in 19,271 men with clinical stage T1-T2 prostate cancer. The primary outcome measures were prostate cancer-specific and overall survival. Comparing 7867 patients who received PADT with 11,404 patients who underwent conservative management, the 10-year cancer-specific survival was lower with the PADT group and overall survival was found to be similar between the groups. However, in the subset with poorly differentiated cancer, PADT was associated with improved cancer-specific, but not overall, survival. This suggests that PADT is not associated with improved survival in the majority of elderly men compared with conservative management.

Original languageEnglish (US)
Pages (from-to)451-453
Number of pages3
JournalAging Health
Issue number5
StatePublished - 2008


  • Hormonal therapy
  • Mortality
  • Primary androgen-deprivation therapy
  • Prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)


Dive into the research topics of 'Does primary androgen-deprivation therapy improve survival for localized prostate cancer?'. Together they form a unique fingerprint.

Cite this